Alarmin IL-33 elicits potent TB-specific cell-mediated responses

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 8, 2015, Pages 1954-1960

  Villarreal, Daniel O ^a   Siefert, Rebekah J ^a   Weiner, David B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adjuvants; DNA vaccines; Interleukin 33; TB vaccines; Tuberculosis

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 33; MYCOBACTERIUM ANTIGEN; PLASMID DNA; TUMOR NECROSIS FACTOR ALPHA; ACYLTRANSFERASE; ANTIGEN 85B, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BCG VACCINE; IMMUNOLOGICAL ADJUVANT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; TUBERCULOSIS; ANIMAL; C57BL MOUSE; GENETICS; IMMUNOLOGY; METABOLISM; SECRETION (PROCESS); TH1 CELL;

ACYLTRANSFERASES; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; INTERFERON-GAMMA; INTERLEUKIN-33; MICE, INBRED C57BL; TH1 CELLS; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA;

EID: 84944452781     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1026499     Document Type: Article

References (35)

1. WHO. Global tuberculosis report 2014. Geneva: World Health Organization, 2014. http://www. who. int/tb/publications/global_report/en/
2. Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339-45; PMID:7475776; http://dx. doi. org/ 10. 1016/S0140-6736(95)92348-9
3. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculosis meningitis and military tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367:1173-80; PMID:16616560; http://dx. doi. org/10. 1016/S0140- 6736(06)68507-3
4. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, et al. Immunjournalapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012; 4:155; PMID:23052295; http://dx. doi. org/10. 1126/ scitranslmed. 3004414
5. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, et al. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery. J Infect Dis 2013; 208:818- 29; PMID:23840043; http://dx. doi. org/10. 1093/ infdis/jit236
6. Reed SG, Orr MT, Fox CB. Key roles of adjuvants in modern vaccines. Nat Med 2013; 19:1597-608; PMID:24309663; http://dx. doi. org/10. 1038/nm. 3409
7. Schijns VEJC, Lavelle EC. Trends in vaccine adjuvants. Expert Rev 2011; 10(4):539-50; PMID:21506650; http://dx. doi. org/10. 1586/erv. 11. 21
8. Cooper AM. Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 2009; 27:393-422; PMID:19302046; http://dx. doi. org/10. 1146/annurev. immunol. 021908. 132703
9. Prezzemolo T, Guggino G, Pio la Manna M, Di Liberto D, Dieli F, Caccamo N. Functional signature of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis. Front Immunol 2014; 5:180; PMID:24795723; http://dx. doi. org/10. 3389/fimmu. 2014. 00180
10. Andersen P, Woodworth JS. Tuberculosis vaccines - rethinking the current paradigm. Trends Immunol 2014; 35:387-95; PMID:24875637; http://dx. doi. org/ 10. 1016/j. it. 2014. 04. 006
11. Oppenheim JJ, Yang D. Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 2005; 17:359-65; PMID:15955682; http://dx. doi. org/ 10. 1016/j. coi. 2005. 06. 002
12. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81:1- 5; PMID:17032697; http://dx. doi. org/10. 1189/jlb. 0306164
13. Chan JK, Roth J, Oppenheim JJ, Tracey KJ, Vogl T, Feldmann M, Horwood N, Nanchahal J. Alarmins: awaiting a clinical response. J Clin Invest 2012; 122:2711-9; PMID:22850880; http://dx. doi. org/ 10. 1172/JCI62423
14. Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Müller S, Iannacone M, Traversari C, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 2004; 5: 825-30; PMID:15272298; http://dx. doi. org/ 10. 1038/sj. embor. 7400205
15. Flohe SB, Bruggemann J, Lendemans S, Nikulina M, Meierhoff G, Flohe S, Kolb H. Human heat shock protein 60 induces maturation of dendritic cells versus a Th1-promoting phenotype. J Immunol 2003; 170:2340-8; PMID:12594256; http://dx. doi. org/ 10. 4049/jimmunol. 170. 5. 2340
16. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL- 33: the new kid in the IL-1 family. Nat Rev Immunol 2010; 10:103-10; PMID:20081870; http://dx. doi. org/10. 1038/nri2692
17. Haraldsen G, Balogh J, Pollheimer J, Sponhiem J, Kuchler. Interleukin- 33-cytokine of dual function or novel alarmin? Trends Immunol 2009; 30:227-33; PMID:19359217; http://dx. doi. org/10. 1016/j. it. 2009. 03. 003
18. Villarreal DO, Weiner DB. Interleukin 33: a switchhitting cytokine. Curr Opin Immunol 2014; 28:102-6; PMID:24762410; http://dx. doi. org/10. 1016/j. coi. 2014. 03. 004
19. Milovanovic M, Volarevic V, Radosavljevic, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res 2012; 52:89-99; PMID:22392053; http://dx. doi. org/10. 1007/s12026-012-8283-9
20. Bonilla WV, Frohlich A, Senn K, Kallert S, Fernandez M, Johnson S, Kreutzfeldt M, Hegazy AN, Schrick C, Fallon PG, et al. The alarmin interleukin-33 drives protective antiviral CD8(Þ) T cell responses. Science 2012; 335:984-9; PMID:22323740; http://dx. doi. org/ 10. 1126/science. 1215418
21. Villarreal DO, Wise MC, Walters JN, Reuschel EL, Choi MJ, Obeng-Adjei N, Yan J, Morrow MP, Weiner DB. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity. Cancer Res 2014; 74:6; PMID:24448242; http://dx. doi. org/ 10. 1158/0008-5472. CAN-13-2729
22. Lee K-S, Kim H-R, Kwak S, Choi KH, Cho JH, Lee YJ, Lee MK, Lee JH, Park SD, Park DS. Association between elevated pleural interleukin-33 levels and tuberculous pleurisy. Ann Lab Med 2013; 33:45-51; PMID:23301222; http://dx. doi. org/10. 3343/alm. 2013. 33. 1. 45
23. Cooper AM Dalton DK, Stewart TA, Griffin JP, Russell DG, Orme IM. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J Exp Med 1993; 168:1322-7; PMID:8245795
24. Flynn JL, Chan J, Triebold J, Dalton DK Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54; PMID:7504064; http:// dx. doi. org/10. 1084/jem. 178. 6. 2249
25. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ, Schreiber R, Mak TW, Bloom BR. Tumor necrosis factor-α Is required in the protective immune response against mycobacterium tuberculosis in mice. Immunity 1995; 2:561- 72; PMID:7540941; http://dx. doi. org/10. 1016/ 1074-7613(95)90001-2
26. Derrick SC, Yabe IM, Yang A, Morris SL. Vaccineinduced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011; 29:2902-9; PMID:21338678; http://dx. doi. org/10. 1016/j. vaccine. 2011. 02. 010
27. Derrick SC, Repique C, Snoy P, Yang AL, Morris S. Immunization with a DNA vaccine cocktail protects mice lacking CD4 cells against an aerogenic infection with Mycobacterium tuberculosis. Infect Immun 2004; 72:1685-92; PMID:14977976; http://dx. doi. org/ 10. 1128/IAI. 72. 3. 1685-1692. 2004
28. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, et al. Multifunctional Th1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-850; PMID:17558415; http://dx. doi. org/10. 1038/nm1592
29. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12:180-190; PMID:22343569
30. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33:153-165; PMID:20732639; http://dx. doi. org/10. 1016/j. immuni. 2010. 08. 004
31. Liao W, Lin JX, Leonard WJ: Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13-25; PMID:23352221; http://dx. doi. org/10. 1016/j. immuni. 2013. 01. 004
32. Grover A, Ahmed MF, Singh B, Verma I, Sharma P, Khuller GK. A multivalent combination of experimental antituberculosis DNA vaccines based on Ag85B and regions of difference antigens. Microbes Infect 2006; 8:2390-9; PMID:16962360; http://dx. doi. org/ 10. 1016/j. micinf. 2006. 04. 025
33. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6. Infec Immun 2001; 69:2773-2778; PMID:11292688; http://dx. doi. org/10. 1128/IAI. 69. 5. 2773-2778. 2001
34. Villarreal DO, Walters J, Laddy DJ, Yan J, Weiner DB. Multivalent TB vaccines targeting the esx gene family generate potent and broad cell-mediated immune responses superior to BCG. Hum Vaccin Immunother 2014; 10(8); PMID:25424922; http://dx. doi. org/ 10. 4161/hv. 29574. [Epub ahead of print]
35. Yan J, Villarreal DO, Racine T, Chu JS, Walters JN, Morrow MP, Khan AS, Sardesai NY, Kim JJ, Kobinger GP, et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine 2014; 32:2833-42; PMID:24631084; http://dx. doi. org/10. 1016/j. vaccine. 2014. 02. 038